4-Benzyloxy-γ-sultone derivatives: Discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus

Journal of Medicinal Chemistry

Volumn 52, Issue 6, 2009, Pages 1582-1591

  De Castro, Sonia ^a   García Aparicio, Carlos ^a   Andrei, Graciela ^b   Snoeck, Robert ^b   Balzarini, Jan ^b   Camarasa, María José ^a   Velázquez, Sonsoles ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4 TETRAHYDRONAPHTHALENE 2 SPIRO 5' (4' BENZYLOXY 5'H 1',2' OXATHIOLE 2',2'DIOXIDE); 4 BENZYLOXY 5 DIPHENYLMETHYL 5 METHYL 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 4 BENZYLOXY 5,5 DIETHYL 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 5 BENZYL 4 BENZOYLOXY 5 ETHYL 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 4 BENZYLOXY 5 ETHYL 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 4 BENZYLOXY 5 ISOBUTYL 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 4 BENZYLOXY 5 ISOPROPYL 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 4 BENZYLOXY 5 METHYL 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 4 BENZYLOXY 5 PROPYL 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 4 CYANOMETHYLOXY 3 ETHYL 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 4 CYCLOHEXYLMETHOXY 5 ETHYL 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 4 DIPHENYLMETHOXY 5 ETHYL 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 5 ETHYL 4 (2' PHENYLETHOXY) 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 5 ETHYL 4 (3' PHENYLPROPOXY) 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 5 ETHYL 4 (4 TOLUENSULFONYLOXY) 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 5 ETHYL 4 (4' FLUOROBENZYLOXY) 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 5 ETHYL 4 (4' NITROBENZYLOXY) 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 5 ETHYL 4 (4' PHENYLBUTOXY) 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 5 ETHYL 4 (4' TRIFLUOROBENZYLOXY) 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 5 ETHYL 4 (6' PHENYLHEXYLOXY) 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 5 ETHYL 4 DIMETHYLALLYLOXY 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 5 ETHYL 4 METHOXY 5H 1,2 OXATHIOLE 2,2 DIOXIDE; 5 BENZYL 5 ETHYL 4 METHOXYCARBONYLMETHOXY 5H 1,2 OXATHIOLE 2,2 DIOXIDE; ACICLOVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; SULTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; SUBSTITUTION REACTION; VARICELLA ZOSTER VIRUS; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; CYTOMEGALOVIRUS; HERPESVIRUS 3, HUMAN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; NAPHTHALENESULFONATES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 64349096615     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8014662     Document Type: Article

References (34)

1. Ljungman, P.; Griffiths, P.; Paya, C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin.Infect.Dis. 2002, 34, 1094-1097.
2. Ives, D. V. Cytomegalovirus disease in AIDS. AIDS 1997, 11, 1791-1797.
3. Gaytant, M. A.; Steegers, E. A. P.; Semmekrot, B. A.; Merkus, H. M. M. W.; Galama, J. M. D. Congenital cytomegalovirus infection: review of the epidemiology and outcome. Obstet. Gynecol. Surv. 2002, 57, 245-256.
4. Whitley, R. J.; Roizman, B. Herpes simplex virus infections. Lancet 2001, 357, 1513-1518.
5. Laguardia, J. J.; Gilden, D. H. Varicella zoster virus: a re-emerging infection. J. Invest. Dermatol. Symp. Proc. 2001, 6, 183-187.
6. Kennedy, P. G. E. Varicella zoster virus latency in human ganglia. Rev. Med. Virol. 2002, 12, 327-334.
7. Schmader, K. Herpes zoster in older adults. Clin.Infect.Dis. 2001, 32, 1481-1486.
8. Biron, K. K. Antiviral drugs for cytomegalovirus diseases. Antivir. Res. 2006, 71, 154-163.
9. De Clercq, E. Antiviral drugs in current clinical use. J. Clin. Virol. 2004, 30, 115-133.
10. Gilbert, C.; Bestman-Smith, J.; Boivin, G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updates 2002, 5, 88-114.
11. Baldanti, F.; Gerna, G. Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact. J. Antimicrob. Chemother. 2003, 52, 324-330.
12. Evers, D. L.; Komazin, G.; Ptak, R. G.; Shin, D.; Emmer, B. T.; Townsend, L. B.; Drach, J. C. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob. Agents Chemother. 2004, 48, 3918-3927.
13. Krosky, P. M.; Borysko, K. Z.; Nassiri, M. R.; Devivar, R. V.; Ptak, R. G.; Davis, M. G.; Biron, K. K.; Townsend, L. B.; Drach, J. C. Phosphorylation of β-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus. Antimicrob. Aeents Chemother. 2002, 46, 478-486.
14. McGuigan, C.; Pathirana, R. N.; Snoeck, R.; Andrei, G.; De Clercq, E.; Balzarini, J. Discovery of a new family of inhibitors of human cytomegalovirus (HCMV) based upon lipophilic alkyl furano pyrimidine dideoxynucleosides: action via a novel non-nucleosidic mechanism. J. Med. Chem. 2004, 47, 1847-1851.
15. Shute, M. E.; Cudahy, M. M.; Brideau, R. J.; Homa, F. L.; Hopkins, T. A.; Knechtel, M. L.; Oien, N. L.; Pitts, T. W.; Poorman, R. A.; Wathen, M. W.; Wieber, J. L. 4-oxo-4,7-Dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. J. Med. Chem. 2005, 48, 5794-5804.
16. Oien, N. L.; Brideau, R. J.; Hopkins, T. A.; Wieber, J. L.; Knechtel, M. L.; Shelly, J. A.; Anstadt, R. A.; Wells, P. A.; Poorman, R. A.; Huang, A.; Vailancourt, V. A.; Clayton, T. L.; Tucker, J. A.; Wathen, M. W. Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob. Agents Chemother. 2002, 46, 724-730.
17. Hartline, C. B.; Harden, E. A.; Williams-Aziz, S. L.; Kushner, N. L.; Brideau, R. J.; Kern, E. R. Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity. Antivir. Res. 2005, 65, 97-105.
18. Buerger, I.; Reefschlaeger, J.; Bender, W.; Eckenberg, P.; Popp, A.; Weber, O.; Graeper, S.; Klenk, H. D.; Ruebsamen-Waigmann, H.; Hallenberger, S. A novel non-nucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 2001, 75, 9077-9086.
19. Reefschlaeger, J.; Bender, W.; Hallenberger, S.; Weber, O.; Eckenberg, P.; Goldmann, S.; Haerter, M.; Buerger, I.; Trappe, J.; Herrington, J. A.; Haebich, D.; Ruebsamen-Waigmann, H. Novel non-nucleoside inhibitors of cytomegalovirus (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother. 2001, 48, 757-767.
20. Andrei, G.; De Clercq, E.; Snoeck, R. Novel inhibitors ofhuman CMV. Curr. Opin. Invest. Drugs 2008, 9 (2), 132-145.
21. Borthwick, A. D. Design of translactam HCMV protease inhibitors as potent antivirals. Med. Res Rev. 2005, 25, 427-452.
22. Wathen, M. W. Non-nucleoside inhibitors of herpesviruses. Rev. Med. Virol. 2002, 12, 167-178.
23. Bogner, E. Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev. Med. Virol. 2002, 12, 115-127.
24. Martínez, A.; Castro, A.; Gil, C.; Pérez, C. Recent strategies in the development of new human cytomegalovirus inhibitors. Med. Res. Rev. 2001, 21, 227-244.
25. Villarreal, E. C. Current and potential therapies for the treatment of herpes-virus infections. Prog. Drug Res. 2003, 60, 263-307.
26. De Castro, S.; Peromingo, M. T.; Lozano, A.; Camarasa, M. J.; Velazquez, S. Reactivity of the 4-amino-1,2-oxathiole-2,2-dioxide heterocyclic system: a combined experimental and theoretical study. ChemsEur. J. 2008, 14, 9620-9632.
27. Stachel, H.-D.; Drasch, G.; Kunze, J.; Peh, J. (BASFAG) Ger. Offen. 2,431,734. July 2, 1974; Chem. Abstr. 1975, 84, 431, 135626.
28. Zhang, Z.; Liu, G. J.; Wang, Y. L.; Wang, Y. Phase-transfer catalyzed monoalkylation of ethyl 2-(p-tolylsulfonyl)acetate. Synth. Commun. 1989, 19, 1167-1173.
29. Poszávácz, L.; Simig, G. Synthesis of 4-amino-5H-1, 2-oxathiole 2,2 dioxides by cyclization of cyanohydrin mesylates. New routes to β-amino and β-keto sulfonic acids. J. Ore. Chem. 1997, 62, 7021-7023.
30. Snoeck, R.; Andrei, G.; Bodaghi, B.; Lagneaux, L.; Daelemans, D.; De Clercq, E.; Neytes, J.; Bousseau, A.; Nemecek, C.; Roy, C. 2-Chloro-3-pyridin-3- yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral Res. 2002, 55, 413-424.
31. McGuigan, C.; Brancale, A.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J. Novel byciclic furanopyrimidines with dual anti-VZV and HCMV activity. Bioore. Med. Chem. Lett. 2003, 13, 4511-4513.
32. Robins, M. J.; Miranda, K.; Rajwanshi, V. K.; Peterson, M. A.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J. Synthesis and Biological Evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one Base and Nucleoside Derivatives. J. Med. Chem. 2006, 49, 391-398.
33. Gerona-Navarro, G.; Pérez de Vega, M. J.; García- López, M. T.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J.; González-Muñiz, R. From 1-acyl-β-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonyl-azetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors. J. Med. Chem. 2005, 48, 2612-2621.
34. Veron, J.-B.; Enguehard-Gheiffier, C.; Snoeck, R.; Andrei, G.; De Clercq, E.; Gueiffier, A. Influence of 6- or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella zoster virus (VZV). Bioore. Med. Chem. 2007, 7209-7219.